KR20230145361A - G12d 변이 kras 단백의 분해를 유도하기 위한 퀴나졸린화합물 - Google Patents

G12d 변이 kras 단백의 분해를 유도하기 위한 퀴나졸린화합물 Download PDF

Info

Publication number
KR20230145361A
KR20230145361A KR1020237027669A KR20237027669A KR20230145361A KR 20230145361 A KR20230145361 A KR 20230145361A KR 1020237027669 A KR1020237027669 A KR 1020237027669A KR 20237027669 A KR20237027669 A KR 20237027669A KR 20230145361 A KR20230145361 A KR 20230145361A
Authority
KR
South Korea
Prior art keywords
formula
methyl
compound
optionally substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237027669A
Other languages
English (en)
Korean (ko)
Inventor
도모히로 요시나리
히로키 이시오카
에이지 가와미나미
히데유키 와타나베
겐이치 가와구치
가즈유키 구라모토
도모요시 이마이즈미
다카히로 모리카와
히사오 하마구치
스나오 이마다
미츠아키 오쿠무라
다케유키 나가시마
고헤이 이나무라
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20230145361A publication Critical patent/KR20230145361A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237027669A 2021-02-15 2022-02-14 G12d 변이 kras 단백의 분해를 유도하기 위한 퀴나졸린화합물 Pending KR20230145361A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-021656 2021-02-15
JP2021021656 2021-02-15
PCT/JP2022/005582 WO2022173032A1 (ja) 2021-02-15 2022-02-14 Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物

Publications (1)

Publication Number Publication Date
KR20230145361A true KR20230145361A (ko) 2023-10-17

Family

ID=82838828

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027669A Pending KR20230145361A (ko) 2021-02-15 2022-02-14 G12d 변이 kras 단백의 분해를 유도하기 위한 퀴나졸린화합물

Country Status (19)

Country Link
US (2) US12384794B2 (https=)
EP (2) EP4293024B1 (https=)
JP (3) JP7169729B1 (https=)
KR (1) KR20230145361A (https=)
CN (1) CN116848120B (https=)
AR (1) AR124870A1 (https=)
AU (1) AU2022221145A1 (https=)
CA (1) CA3211051A1 (https=)
CL (1) CL2023002383A1 (https=)
CO (1) CO2023010710A2 (https=)
CR (1) CR20230404A (https=)
DO (1) DOP2023000161A (https=)
EC (1) ECSP23067156A (https=)
IL (1) IL305077A (https=)
JO (1) JOP20230190A1 (https=)
MX (1) MX2023009521A (https=)
PE (1) PE20240235A1 (https=)
WO (1) WO2022173032A1 (https=)
ZA (1) ZA202307791B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2022173032A1 (ja) * 2021-02-15 2022-08-18 アステラス製薬株式会社 Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
WO2023119677A1 (en) 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
TW202346270A (zh) 2022-03-11 2023-12-01 日商安斯泰來製藥股份有限公司 用於誘發g12d突變kras蛋白分解之雜環化合物
US20250145631A1 (en) 2022-07-21 2025-05-08 Astellas Pharma Inc. Heterocyclic compound acting on g12d mutant kras protein
TW202412789A (zh) 2022-08-05 2024-04-01 日商安斯泰來製藥股份有限公司 用於誘導突變kras蛋白分解之雜環化合物
EP4570795A1 (en) 2022-08-09 2025-06-18 Astellas Pharma, Inc. Heterocyclic compound for inducing degradation of g12v mutant kras protein
EP4570794A1 (en) 2022-08-09 2025-06-18 Astellas Pharma, Inc. Heterocyclic compound for inhibiting and/or inducing degradation of kras protein
WO2024032747A1 (zh) 2022-08-12 2024-02-15 正大天晴药业集团股份有限公司 三环类化合物及其医药用途
AR130192A1 (es) * 2022-08-12 2024-11-13 Astellas Pharma Inc Combinaciones antineoplásicas que comprenden quimioterapia
AR130191A1 (es) * 2022-08-12 2024-11-13 Astellas Pharma Inc Combinaciones antineoplásicas que comprenden tratamiento dirigido
WO2024034123A1 (ja) * 2022-08-12 2024-02-15 アステラス製薬株式会社 複素環化合物を含む医薬組成物
CN115873018B (zh) * 2022-11-18 2024-03-15 中国药科大学 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
KR20260016466A (ko) * 2023-03-27 2026-02-03 셴젠 이오노바 라이프 사이언스 시오., 엘티디. Kras(g12d) 단백질의 분해 및 억제를 위한 화합물
AR133027A1 (es) * 2023-06-22 2025-08-20 Astellas Pharma Inc Composición farmacéutica que comprende un compuesto de quinazolina
AR133028A1 (es) 2023-06-22 2025-08-20 Astellas Pharma Inc Composición farmacéutica que comprende un degradador de todas las kras
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
TW202528311A (zh) 2023-09-13 2025-07-16 日商安斯泰來製藥股份有限公司 包含具有ｇ１２ｄ突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024360867A1 (en) * 2023-10-10 2026-04-02 Aurigene Oncology Limited Substituted tricyclic compounds as kras degraders
WO2025108479A1 (en) * 2023-11-24 2025-05-30 Shenzhen Ionova Life Science Co., Ltd. Compounds for degradation or inhibition of kras mutant proteins and uses thereof
WO2025151765A1 (en) * 2024-01-10 2025-07-17 1200 Pharma Llc Kras g12d degraders and uses thereof
TW202545930A (zh) * 2024-01-24 2025-12-01 日商安斯泰來製藥股份有限公司 用於誘導kras蛋白質之分解之雜環化合物
TW202545934A (zh) * 2024-02-05 2025-12-01 日商安斯泰來製藥股份有限公司 包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體
WO2025168124A1 (zh) * 2024-02-08 2025-08-14 杭州多域生物技术有限公司 喹唑啉类化合物、其药物组合物及其应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106643A2 (en) 2012-01-12 2013-07-18 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US20180015087A1 (en) 2016-07-13 2018-01-18 Araxes Pharma Llc Conjugates of cereblon binding compounds and g12c mutant kras, hras or nras protein modulating compounds and methods of use thereof
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021051034A1 (en) 2019-09-13 2021-03-18 Biotheryx, Inc. Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2021107160A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
CN115803030A (zh) 2020-04-06 2023-03-14 阿维纳斯企业公司 用于kras靶向降解的化合物和方法
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
US20240092803A1 (en) 2021-01-08 2024-03-21 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022173032A1 (ja) * 2021-02-15 2022-08-18 アステラス製薬株式会社 Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
WO2023119677A1 (en) * 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106643A2 (en) 2012-01-12 2013-07-18 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US20180015087A1 (en) 2016-07-13 2018-01-18 Araxes Pharma Llc Conjugates of cereblon binding compounds and g12c mutant kras, hras or nras protein modulating compounds and methods of use thereof
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021051034A1 (en) 2019-09-13 2021-03-18 Biotheryx, Inc. Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2021107160A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS Cent. Sci., 2020, 6, p1367-1375
Cell. Chem. Biol., 2020, 27, p19-31

Also Published As

Publication number Publication date
US20240182483A1 (en) 2024-06-06
JP2026048973A (ja) 2026-03-17
PE20240235A1 (es) 2024-02-16
EP4293024B1 (en) 2026-04-08
US20250340561A1 (en) 2025-11-06
IL305077A (en) 2023-10-01
CA3211051A1 (en) 2022-08-18
JOP20230190A1 (ar) 2023-08-14
CN116848120B (zh) 2026-02-13
TW202245751A (zh) 2022-12-01
BR112023015067A2 (pt) 2023-10-03
CN116848120A (zh) 2023-10-03
EP4706774A3 (en) 2026-04-15
EP4706774A2 (en) 2026-03-11
US12384794B2 (en) 2025-08-12
AU2022221145A1 (en) 2023-09-21
DOP2023000161A (es) 2023-09-29
MX2023009521A (es) 2023-08-24
EP4293024A4 (en) 2025-03-05
CO2023010710A2 (es) 2023-09-18
ECSP23067156A (es) 2023-10-31
AR124870A1 (es) 2023-05-17
JP7169729B1 (ja) 2022-11-11
JP2022191505A (ja) 2022-12-27
WO2022173032A1 (ja) 2022-08-18
JPWO2022173032A1 (https=) 2022-08-18
EP4293024A1 (en) 2023-12-20
ZA202307791B (en) 2024-12-18
CR20230404A (es) 2023-09-21
CL2023002383A1 (es) 2024-01-19
JP7851842B2 (ja) 2026-04-27

Similar Documents

Publication Publication Date Title
JP7851842B2 (ja) Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
JP7640945B2 (ja) キナゾリン化合物を含有する医薬組成物
KR20240162042A (ko) G12d 변이 kras 단백의 분해를 유도하기 위한 복소환 화합물
KR20250044266A (ko) 변이 kras 단백의 분해를 유도하기 위한 복소환 화합물
WO2024034593A1 (ja) Ｇ１２ｖ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物
KR20250036820A (ko) G12d 변이 kras 단백에 작용하는 복소환 화합물
WO2024034591A1 (ja) Ｋｒａｓタンパクを阻害及び／又は分解誘導するための複素環化合物
RU2856363C1 (ru) Соединение хиназолина для индукции деградации белка kras с мутацией g12d
TWI922584B (zh) 用於誘發g12d突變kras蛋白之分解之喹唑啉化合物
HK40096919A (zh) 用於诱导g12d突变kras蛋白分解的喹唑啉化合物
EA049356B1 (ru) Соединение хиназолина для индукции деградации белка kras с мутацией g12d
CN118829640A (zh) 用于诱导g12d突变kras蛋白分解的杂环化合物
HK40109307A (zh) 包含喹唑啉化合物的药物组合物
CA3263711A1 (en) Heterocyclic compound for inducing degradation of mutant kras protein
EA050814B1 (ru) Фармацевтическая композиция, содержащая хиназолиновое соединение
BR112023015067B1 (pt) Composto de quinazolina para induzir a degradação de proteína kras g12d mutante, composição farmacêutica compreendendo o mesmo e uso deste para tratar câncer pancreático

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902